Plantar warts are benign skin lesions caused by infection with the human papillomavirus (HPV). They develop on the soles of the feet and may be pushed inward by weight-bearing forces, producing a thickened lesion that can resemble a corn or callus. Although some plantar warts are painless and disappear spontaneously, others persist, spread, or cause considerable discomfort during standing and walking. Standard treatments include salicylic acid, cryotherapy, curettage, and other destructive or immunomodulatory methods. Cimetidine, a medicine best known for reducing stomach acid, has also been investigated as an oral treatment for warts. Its use remains controversial because the proposed biological rationale is plausible, but clinical evidence is inconsistent.
Cimetidine is a histamine H2-receptor antagonist traditionally used to treat peptic ulcer disease and gastro-oesophageal reflux. Interest in cimetidine for warts arose from observations that, at doses higher than those normally used for gastric disorders, it might alter immune function. Clearance of HPV depends heavily on cell-mediated immunity. Cimetidine has been proposed to suppress regulatory T-cell activity and enhance immune responses involving interleukin-2 and other cytokines. In theory, this could help the body recognise and eliminate HPV-infected keratinocytes. Unlike destructive treatments, oral cimetidine might act on multiple lesions simultaneously and does not cause the pain, blistering, or local tissue damage associated with cryotherapy or surgery.
Early uncontrolled studies and case reports produced encouraging results, particularly in children and patients with numerous or recalcitrant warts. Reported regimens have commonly involved approximately 20–40 mg/kg per day, up to the prescriber’s maximum dose, for several weeks or months. These findings generated enthusiasm because cimetidine is widely available and usually well tolerated. It appeared especially attractive for children who feared painful procedures and for people with widespread warts that would be impractical to treat individually. However, improvement in an uncontrolled study cannot establish that the medicine caused wart clearance. Warts often resolve naturally as the immune system develops an effective response, making spontaneous resolution a major confounding factor.
More rigorous evidence has been less persuasive. Randomised, placebo-controlled trials have generally failed to demonstrate a clear and consistent advantage for cimetidine over placebo in treating common warts. Reviews of wart therapies therefore do not regard oral cimetidine as a reliably effective first-line treatment. Differences in participant age, wart location, treatment dose, treatment duration, and immune status may partly explain the conflicting results. Some individuals could benefit, but current evidence does not identify them confidently. Evidence specifically concerning plantar warts is also limited; results involving warts on the hands or mixed anatomical sites cannot automatically be applied to lesions exposed to pressure on the foot.
Safety is another important consideration. Cimetidine is generally tolerated, but adverse effects can include headache, dizziness, diarrhoea, nausea, fatigue, and skin rash. Less common effects include confusion, liver abnormalities, breast enlargement, and sexual dysfunction, especially with higher doses or prolonged use. The drug inhibits several hepatic cytochrome P450 enzymes and can increase blood concentrations of medicines such as warfarin, phenytoin, and theophylline. Dosage adjustment may be required in renal impairment. Consequently, high-dose cimetidine should not be started without assessment by a doctor, pharmacist, or qualified prescriber. Its off-label status for warts should also be explained so that patients understand the uncertainty surrounding benefit.
Correct diagnosis is essential before any treatment is chosen. A plantar wart often interrupts normal skin lines and may display pinpoint bleeding or dark dots representing thrombosed capillaries. Nevertheless, corns, calluses, foreign-body reactions, and occasionally malignant lesions can look similar. A podiatrist or medical practitioner should evaluate lesions that are atypical, rapidly changing, bleeding, ulcerated, or resistant to treatment. People with diabetes, peripheral neuropathy, poor circulation, or immunosuppression require particular caution and should avoid unsupervised destructive treatments because injury may heal poorly or become infected.
For most patients, treatments with stronger supporting evidence should be considered first. Regular application of topical salicylic acid, after careful soaking and gentle reduction of excess keratin, remains a common first-line option when it is safe. Cryotherapy may also be offered, although it can be painful and is not consistently superior to salicylic acid for plantar warts. Pressure-relieving padding, suitable footwear, keeping the lesion covered, and avoiding picking may reduce discomfort and transmission. Persistent or troublesome lesions may require specialist assessment and discussion of further options.
Cimetidine offers an interesting systemic and potentially painless approach to plantar warts through its proposed immunomodulatory effects. Positive case reports and uncontrolled studies suggest possible benefit for selected patients, particularly those with multiple or difficult warts. However, better-designed trials have not shown dependable superiority over placebo, and evidence specific to plantar lesions remains weak. Cimetidine should therefore not be presented as a proven routine cure. If considered for a carefully selected patient, it should be prescribed with attention to dosage, kidney function, adverse effects, drug interactions, and informed consent. At present, its most appropriate role is an off-label, secondary option rather than a replacement for established care.
References
- Sterling, J. C., Gibbs, S., Haque Hussain, S. S., Mohd Mustapa, M. F., & Handfield-Jones, S. E. (2014). British Association of Dermatologists’ guidelines for the management of cutaneous warts 2014. British Journal of Dermatology, 171(4), 696–712.
- Lipke, M. M. (2006). An armamentarium of wart treatments. Clinical Medicine & Research, 4(4), 273–293.
- Yilmaz, E., Alpsoy, E., & Basaran, E. (1996). Cimetidine therapy for warts: A placebo-controlled, double-blind study. Journal of the American Academy of Dermatology, 34(6), 1005–1007.
- Rogers, C. J., Gibney, M. D., Siegfried, E. C., Harrison, B. R., & Glaser, D. A. (1999). Cimetidine therapy for recalcitrant warts in adults: Is it any better than placebo? Journal of the American Academy of Dermatology, 41(1), 123–127.